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Impaired awareness of hypoglycaemia (IAH) is defined as ‘a dimin-
ished ability to perceive the onset of acute hypoglycaemia’.1 IAH 
affects 20%-25% of all people with type 1 diabetes, and of concern, 
the incidence of IAH has not changed in the last 2-3 decades despite 
the introduction of insulin analogues and improved insulin delivery 
systems.2 In people with type 1 diabetes, IAH increases the risk of 
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Aim: This pilot study aimed to investigate whether a 4-week programme of inter-
mittent high-intensity training (HIT) will improve counterregulatory responses and 
improve hypoglycaemia awareness in adults with type 1 diabetes who have been 
exposed to recurrent hypoglycaemia.
Methods: Adults with type 1 diabetes who have been exposed to recurrent hy-
poglycaemia	will	 be	 recruited	 from	NHS	Tayside,	 Scotland.	All	 participants	have	a	
4-week run-in period to optimize glycaemic control and to receive instruction in 
hypoglycaemia avoidance using insulin dose adjustment and real-time continuous 
glucose	monitoring	 (CGM).	Following	 this,	 they	will	 undergo	a	baseline	90-minute	
hyperinsulinaemic hypoglycaemic clamp to assess symptomatic, cognitive and hor-
monal	counterregulatory	responses.	Subsequently,	participants	will	be	randomized	
in a parallel-group design to either undergo a 4-week intervention with HIT or to no 
exercise	with	both	groups	using	CGM	throughout	and	receiving	additional	advice	on	
hypoglycaemia avoidance. Participants in the HIT arm of the trial will be instructed to 
exercise	3	times	a	week	on	a	cycle	ergometer	and	asked	to	achieve	≥	90%	max	heart	
rate during each period of exercise. On completion of the intervention period, all sub-
jects then undergo a second matched hyperinsulinaemic hypoglycaemic clamp study.
Discussion: This pilot study will determine whether high-intensity exercise may offer a 
novel approach to restore hypoglycaemic awareness in type 1 diabetes (International 
Standard	Randomised	Controlled	Trials	No:	ISRCTN15373978).
K E Y W O R D S
adrenaline, behaviour, counterregulation, diabetes, exercise, habituation, hypoglycaemia, 
impaired awareness
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severe hypoglycaemia (defined as the need for external assistance 
to recover) by up to sixfold.3	 IAH	 is	 an	 acquired	 abnormality	 that	
is essentially a complication of insulin therapy; it should be placed 
alongside retinopathy, neuropathy and nephropathy as its morbidity 
and mortality can be just as serious and disabling. The underlying 
mechanisms that lead to the development of IAH are unclear; how-
ever, it has been well established in multiple studies in people with 
and without type 1 diabetes that IAH can develop by inducing one 
or more episodes of experimentally induced hypoglycaemia.4 In ad-
dition,	the	greater	the	frequency	of	incidence	exposure	to	hypogly-
caemia, the greater the degree of suppression of symptomatic and 
hormonal counterregulatory responses (CRR), a process that can be 
reversed through strict hypoglycaemia avoidance.5-7
Habituation is a form of adaptive memory that develops in 
many organisms in response to a repeated, often stressful stim-
ulus.8 Habituation is defined as a ‘reduction of the psychological, 
behavioural or physiological response to a stimulus as a result of 
repeated or prolonged exposure’.8,9 This definition of a habituated 
response is consistent with the changes in CRR evoked by repeated 
hypoglycaemia in people with type 1 diabetes where there is also a 
progressive reduction or loss of psychological (anxiety), behavioural 
(food seeking) and physiological (symptom and hormonal) CRR.8-10 
This suggests the hypothesis that IAH develops through habituation 
to repeated hypoglycaemia. To test this hypothesis, we recently con-
ducted two proof-of-concept studies in rodents11 and humans.12 In 
these two studies, we sought to determine whether IAH could be 
at least temporarily improved by the introduction of a novel stress 
stimulus, a phenomenon referred to as dishabituation and a key fea-
ture of habituation. Consistent with our hypothesis, we reported 
that a single 20-minute programme of high-intensity exercise signifi-
cantly	augmented	the	CRR	to	subsequent	hypoglycaemia	in	both	the	
rodent model11 and humans with long-duration type 1 diabetes and 
IAH.12 However, while we have demonstrated that a single episode 
of HIT can at least temporarily improve the counterregulatory defect 
induced by recurrent hypoglycaemia, it remains possible that the ef-
fect is (a) not sustained or (b) individuals may over time adapt to the 
novel dishabituating stimulus.
2  | AIM
To investigate whether a 4-week programme of intermittent high-
intensity exercise will improve counterregulatory responses and re-
store hypoglycaemia awareness in adults with T1D and IAH beyond 
the benefits that may be achieved through optimal treatment.13
3  | PARTICIPANTS AND METHODS
3.1 | Study design
This is a randomized, parallel-group, single-centre pilot study con-
ducted	 in	 NHS	 Tayside,	 Scotland.	 Up	 to	 32	 participants	 will	 be	
randomized 1:1 to intervention; 4-week programme of intermittent 
high-intensity exercise and continuous glucose monitoring, or con-





glucose or flash glucose readings of <4.0 mmol/L a week, based 
on long-term history and up to 90 days flash glucose monitoring 
or	CGM).
Inclusion criteria were as follows:
•	 Adults	≥18	and	≤55	years
• Type 1 diabetes
a. >5 years' disease duration
b. HbA1c < 75 mmol/L
•	 On	intensive	insulin	therapy	(CSII	or	MDI)
Exclusion criteria were as follows:
• Competitive sportsman/woman
• History of significant heart disease
• Ischaemic heart disease, congestive cardiac failure or cardiac 
surgery
• Treatment with beta-blockers
• Treatment with oral steroids within the last 6 months
• Anaemia (Hb < 120 g/L for women, Hb < 130 g/L for men)
•	 Renal	impairment	(eGFR	< 60)
• History of significant lung disease—that limits exercise
• History of significant neurological disease—those with a history 
of seizures second to hypoglycaemia must be seizure-free for 
12 months prior to consent.
• High-risk foot disease
• Previous amputation of toes/foot/leg
• Pregnant women or breastfeeding mothers
•	 Participation	in	HIT	or	equivalent	in	past	6	months
• Physical ability that may limit exercise






ing visit where informed written consent will be given and eligibil-
ity confirmed. This will involve a review of their medical history, 
recent blood results and flash glucose monitoring if applicable 
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and	completion	of	three	questionnaires:	Gold	et	al,14 Clarke et al15 
and	 DAFNE,16 to determine degree of subjective hypoglycaemia 
awareness.





All participants will then enter an initial 4-week run-in period. During 
this time, their glycaemic control will be optimized through insulin 
dose adjustment, review of carbohydrate counting/ratios and in-
structions on hypoglycaemia avoidance. This will be done via a phone 
call or email once a week by the Clinical Research Fellow (CRF).
During the 4-week run-in period, there will be one study visit 
(visit 2), which takes place in week 1 or 2. During this visit, all par-
ticipants will be taught how to fit the real-time continuous glucose 
monitor	(CGM)	(Dexcom	G6;	Dexcom)	and	shown	how	it	works.
For	 those	 participants	 in	 the	 HIT&CGM	 group,	 during	 visit	 2	
medical history will be detailed and participants will undergo clin-
ical examination. An electrocardiogram and vital signs including 
blood pressure and heart rate will be checked as a safety measure. 
Participants will undergo an assessment of their baseline fitness by 
carrying out a VO2 peak and heart rate peak assessment on a cycle 
ergometer	 (Corival,	 Lode;	 Metamax	 3B,	 CORTEX	 Biophysik).	 The	
VO2 peak will be performed as an incremental maximum fitness test; 
2 minutes at rest to ensure accurate readings followed by 5-minute 
warm-up	at	25w,	cycling	at	a	cadence	of	40-60RPM.	The	incremen-
tal protocol will then begin at 35w, increasing by 15w per minute 
while	 maintaining	 a	 cadence	 of	 approximately	 60RPM.	 Rating	 of	
perceived exertion (RPE) will be assessed every minute during the 
test	using	the	Borg	scale.17 The test will continue until VO2 peak is 
reached. Three of the following four criteria need to be satisfied:
•	 RPE	≥	18
• Respiratory exchange ratio >1.1
• Volitional fatigue
•	 Maximum	estimated	heart	rate	(220-age)
The peak heart rate reached will be used to design the HIT pro-
gramme for each participant. Participants will be given standard advice 
regarding insulin dose adjustments prior to and following the VO2 peak 
assessment.18
This visit will take place during the first 2 weeks of the run-in 
period to allow any effect from VO2 max and heart rate peak assess-
ment to have worn off.
4.3 | Experimental Hypoglycaemia: 
Hyperinsulinaemic hypoglycaemic clamp study
At the end of the 4-week run-in period, participants will return to 
the Clinical Research Centre for visit 3 where they will undergo a hy-
perinsulinaemic hypoglycaemic clamp.19 They will have been fasted 
from	mid-night	 (drinking	 clear	 fluids	 only).	 CGM	 data	will	 first	 be	
analysed to ensure no significant hypoglycaemia (<3.0 mmol/L for 
≥20	minutes)20,21 in the preceding 24 hours. If there is evidence of 
hypoglycaemia, the study will be postponed and the visit repeated. 
If there is no evidence of hypoglycaemia, each participant will then 
undergo a controlled 90-minute hyperinsulinaemic hypoglycaemic 
(2.5 mmol/L) clamp study.
In	 this	 procedure,	 insulin	 (0.3	 U/mL)	 is	 infused	 at	 50	 mL/h	
for priming purposes until the blood glucose drops to below 
7	mmol/L,	after	which	a	rate	of	1.5	mU/kg/min	will	be	maintained	




cose at predetermined levels. In this study, euglycaemia (glucose 
target 5.0 mmol/L) is initially achieved and maintained for the first 
30	minutes	of	the	glucose	clamp	study,	and	subsequently,	blood	
glucose will be reduced over 30 minutes to a target plasma glu-
cose level of 2.5 mmol/L, which is then maintained for a further 
60 minutes before glucose levels are returned to the euglycaemic 
range.
Blood	samples	will	be	taken	every	30	minutes	during	the	hyper-
insulinaemic euglycaemic and hypoglycaemic clamp (t =	−30,	0,	30,	
60,	90	minutes).	Glucose,	lactate,	glucagon,	adrenaline,	noradrena-
line, insulin and cortisol will be measured.
In addition, at each 30-minute time point (t =	 −30,	 0,	 30,	 60,	
90 minutes) participants' cognitive function will be assessed using 
the	Digit	 symbol	 substitution	 test	 (DSST22) and 4-choice reaction 
time test (4CRT23).	The	Edinburgh	Hypoglycaemia	Symptom	(EHS24) 
score will be used to assess symptom awareness at each of these 
time points. At the start of the hyperinsulinaemic hypoglycaemic 
clamp,	 participants	 will	 be	 asked	 to	 complete	 the	 World	 Health	
Organisation—Five	Well-Being	 Index25	 (WHO-5)	 as	 a	 measure	 of	
well-being.
F I G U R E  1   High-intensity training programme
5 minutes
Cool downHITWarm-up Rest Rest Rest
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Blood	 samples	will	 be	 centrifuged	 and	 decanted	 into	micro-
tubes,	which	will	be	stored	at	−80°C.	When	the	study	has	been	





will continue with their usual standard of care but with the use of 
CGM	 to	 optimize	 glycaemic	 control	 and	 aid	 hypoglycaemia	 avoid-
ance.	Participants	within	the	HIT&CGM	group	will	undergo	the	HIT	
programme (Figure 1), three times a week for the 4-week interven-
tion	period	plus	using	the	CGM	to	optimize	glycaemic	control	and	
avoid hypoglycaemia. In addition, instructions on insulin and carbo-
hydrates adjustment before and after exercise are provided accord-
ing to recent guidelines.18
The	 aim	 of	 the	HIT	 programme	 is	 to	 reach	 ≥	 90%	 peak	 heart	
rate obtained during the VO2 peak assessment. The HIT programme 
will be carried out on an exercise bike at a local gym convenient for 
the participant. They will be asked to gently cycle for 5 minutes to 
warm-up and then increase the resistance and their revolutions per 
minute	 (RPM)	 for	30	 seconds.	This	 is	 followed	by	2-minute	 active	
recovery and repeated 4 times with a 5-minute cool-down period at 
the end (Figure 1).
A member of the research team will attend the first exercise ses-
sion with each participant to ensure they are familiar with the proto-
col	and	able	to	complete	it.	Participants	in	the	HIT&CGM	group	will	
be given heart rate monitors (Polar Vantage M and H10; Polar Electro 
OY) to use during their exercise sessions to record their heart rate 
during each session.
During the 4-week intervention period, there will be a flexible 
weekly	study	visit	for	both	study	groups.	During	this	visit,	CGM	data	
will be downloaded, and advice given to insulin dose adjustment to 
optimize glycaemic control and aid avoidance of hypoglycaemia. In 
F I G U R E  2  Study	flow	diagram
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addition, heart rate data will be downloaded to ensure that all those 
in	 the	HIT	 group	 are	 reaching	 their	 heart	 rate	 target	 (≥90%	max)	
during the HIT sessions.
There will be a 4- to 7-day break at the end of the intervention pe-
riod	prior	to	the	hyperinsulinaemic	hypoglycaemic	clamp	study,	visit	8.
Study	 visit	 8	 and	 the	 hyperinsulinaemic	 hypoglycaemic	 clamp	
method will be identical to visit 3 and will be the final study visit. The 
study will be completed when the final participant completes their 
final visit (Figure 2).
4.5 | Study outcomes
4.5.1 | Primary
• The difference in the adrenaline response to hypoglycaemia fol-
lowing the HIT or control interventions
4.5.2 | Secondary
• Changes in awareness of hypoglycaemia and symptom scores—
Edinburgh	Hypoglycaemia	Symptom	(EHS)	score.




• Changes in other counterregulatory hormones—glucagon, nor-
adrenaline	(NA),	lactate	and	cortisol.
4.6 | Sample size and power calculation
This is a pilot study and therefore cannot be powered by any previ-
ous studies as to the best of our knowledge there has not been a 
study of its type before.
We	will	aim	to	recruit	up	to	16	participants	to	each	study	group	







The randomization involved will relate to which intervention group 
participants	 are	 allocated	 to	 (HIT&CGM	 or	 CGM	 alone	 (control)).	
Randomization will be carried out by an independent individual, at 
the	University	 of	 Dundee.	 Randomization	will	 be	 done	 in	 a	 GCP-
compliant manner using http://www.rando mizat ion.com/.
Randomization	will	be	carried	out	using	a	validated	Web-based	
block	randomization	generator	to	ensure	that	an	equal	number	of	
participants are assigned to each intervention at baseline. Once 
the randomization has taken place, the allocation list will be con-
cealed from the CI and CRF until the recruit has been consented. 
The CRF will be informed of the intervention allocation and will 
inform the participant once they have consented to take part in 
the study.
5  | DATA COLLEC TION, MANAGEMENT 
AND ANALYSIS
5.1 | Data collection
The data will be collected by the CRF or delegated member of the 
research	 team	on	a	paper	case	 report	 form	with	subsequent	 tran-
scription to an electronic case report form. Electronic storage will be 
in an encrypted form on a password-protected device. The medical 
notes will act as source data for medical history, any data relating to 
general medical history will be filed in the notes.
5.2 | Statistical methods
For the primary and secondary end points, a mixed model will be 




A data monitoring committee is not considered necessary as this is 
a relatively small trial. An experienced Chief Investigator will super-
vise the CRF. All local protocols will be followed with regard to data 
monitoring.
6  | ETHIC S AND DISSEMINATION
Ethics	approval	was	obtained	by	the	South	East	of	Scotland	Research	
Ethics	Service	(18/SS/0160).
The report from the clinical trial will be used for publication and 
presentation at scientific meetings. The trial investigators will pub-
lish the results in writing or via oral presentation.
The	 trial	 has	 been	 registered	 with	 an	 International	 Standard	
Randomised	 Controlled	 Trials	 Number	 (ISRCTN15373978).	 It	 was	
registered before the enrolment of patients.
Should	 any	 protocol	modifications	 arise,	 these	will	 be	 decided	
by the CI and CRF. The protocol will then be reviewed by the trial 
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sponsor, who will decide whether further notification to the relevant 
authorities	is	required.
6.1 | Discussion
Approximately 20%-30% of all people with type 1 diabetes have 
impaired awareness of hypoglycaemia,2 a condition that negatively 
impacts	on	their	quality	of	life	and	that	is	associated	with	significant	
morbidity. The mechanisms behind the development of impaired 
awareness of hypoglycaemia are not yet fully understood. There are 
many features of this phenomenon that are however in keeping with 
a	 habituated	 response,	 as	 described	 by	 Thompson	 and	 Spencer,9 
and recently reviewed by our group.4	Moreover,	a	cardinal	feature	
of a habituated response is that it can be at least temporarily re-
stored following the introduction of a novel, usually strong, stimu-
lus: dishabituation.9	Using	a	single	episode	of	HIT	as	a	dishabituating	
stimulus to test this concept, we were recently able to demonstrate 
improvements in CRR to hypoglycaemia in both rodents11 and hu-
mans with long-standing type 1 diabetes.12 However, a single epi-
sode of HIT is unlikely to have a sustained effect and to fully restore 
hypoglycaemia awareness in individuals with type 1 diabetes who 
have been exposed to multiple episodes of hypoglycaemia over 
many	years.	In	HIT4HYPOS,	we	will	examine	in	a	small,	experimen-
tal study whether a 4-week intervention with HIT (12 episodes in 
total) in addition to standard care for people experiencing recurrent 
hypoglycaemia will have sustained benefits on symptom awareness 
and counterregulatory hormone responses to hypoglycaemia. If suc-
cessful, this will confirm that impaired awareness of hypoglycaemia 
develops through habituation to recurrent hypoglycaemia and that 
dishabituation offers a novel, therapeutically attractive approach to 
improving and potentially treating hypoglycaemia awareness in type 
1 diabetes. If this study proves to be successful, we may also need 
to consider other non–exercise-related interventions (eg cold expo-
sure)	that	may	prove	equally	beneficial	and	applicable	to	those	who	
have difficulty with exercise.
6.2 | Limitations
As this is a pilot study, power calculations have not been carried 
out. A clear limitation is that this is a small single-centre study. 
The study is looking at people with type 1 diabetes within the 
working population, there are eight study visits, two of which are 
hyperinsulinaemic hypoglycaemic clamp studies (5 hours) as such 
a dropout rate has been considered, recruiting up to 32 partici-
pants	to	allow	for	dropouts.	We	are	carrying	out	a	parallel-group	
study as it is not known how long any lasting effect from the in-
tervention may have on individuals' response to hypoglycaemia, 
we are therefore not be able to carry out a randomized crosso-
ver study. Although the hyperinsulinaemic hypoglycaemic clamp 
is	 the	 gold	 standard	 technique	 for	 assessing	 counterregulatory	
responses to hypoglycaemia,19 the studies are conducted under 
strictly controlled conditions in a laboratory, and as such, the 
experience of hypoglycaemia may not fully reflect its real-world 
experience.
In	 summary,	 HIT4HYPOS	 is	 a	 single-centre	 randomized	 paral-
lel-group study investigating whether dishabituation with high-in-
tensity exercise can be used as a novel treatment to improve 
hypoglycaemia awareness in people with long-duration type 1 dia-
betes. This study will provide useful insights in this field where the 
underlying cause of this common complication is not yet fully under-
stood and treatment options remain limited.
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